Premium
Journey in reverse: TTP from bedside to blood bank to bench
Author(s) -
Moake Joel L.
Publication year - 2007
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.20110
Subject(s) - medicine , apheresis , thrombotic thrombocytopenic purpura , etiology , bench to bedside , blood bank , intensive care medicine , platelet , medical emergency , medical physics
Thrombotic thrombocytopenic purpura (TTP) is the most extensive and dangerous intravascular platelet clumping disorder. For more than a half‐century after its initial recognition, mortality was near 100% and the etiology totally obscure. Then, in the late 1970s to early 1980s, empiric, but successful, therapy by a few clinician/blood bank partnerships was followed by sudden laboratory insight into pathophysiology. The discussion that follows was prepared in conjunction with the 2006 Francis Morrison, M.D., Memorial Lecture at the 27th Annual Meeting of the American Society for Apheresis. J. Clin. Apheresis. © 2006 Wiley‐Liss, Inc.